Corporate Banner
Satellite Banner
Molecular & Clinical Diagnostics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Genomic Vision to extend its strategic R&D alliance with Quest Diagnostic

Published: Tuesday, June 11, 2013
Last Updated: Tuesday, June 11, 2013
Bookmark and Share
Under the agreement, Quest Diagnostics will invest in the planned development of a lab-developed test for a hereditary genetic disease.

The company will also collaborate with Genomic Vision to automate the testing process and improve turnaround times for tests that employ DNA combing, a technique from Genomic Vision. Additional terms were not disclosed.

"This development is based on the complementary nature of our expertise. The new automated process will help leverage the potential of DNA combing for testing of large populations, which in turn may help improve detection of diseases such as certain cancers and neurological disorders ", stated Aaron Bensimon, CEO of Genomic Vision.

"This development program should make an automated platform available to our customers by the end of 2013, increasing the throughput of our current platform by an order of magnitude", explained Dr. Bensimon.

Genomic Vision and Quest Diagnostics announced a strategic alliance agreement in July 2011 giving Quest exclusive rights in the United States and certain other territories to develop and sell diagnostic tests based on Genomic Vision's molecular combing technology. Quest Diagnostics (7.4 billion dollars in 2012 revenues with 41,000 employees) has also taken an equity stake in the French biotech company.

Since that time, Quest Diagnostics has adapted the molecular combing technique to a commercial laboratory, streamlined and automated processes and successfully validated an improved molecular combing assay for the genetic disorder facio-scapulo-humeral muscular dystrophy (FSHD). Quest Diagnostics expects to launch the FSHD lab-developed test this summer.

Quest Diagnostics is also exploring market opportunities for a lab-developed test for Lynch Syndrome, which genetically predisposes an individual to colorectal cancer, based on DNA combing.

 In 2012, Genomic Vision launched its first test in Europe designed to diagnose facio-scapulo-humeral muscular dystrophy (FSHD), the second most prevalent muscular dystrophy disorder affecting 1 in 10,000 to 1 in 20,000 people.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,000+ scientific posters on ePosters
  • More than 4,500+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Genomic Vision to Extend its Strategic R&D Alliance with Quest Diagnostics
Quest Diagnostics will invest in the planned development of a lab-developed test.
Friday, June 14, 2013
Scientific News
AACR 2016: Cancer Immunotherapy and Beyond
At this year's meeting there was a palpable buzz around subjects ranging from microbiomics to the tumor microenvironment and cancer vaccines, big data to in vitro and in vivo modeling and drug delivery (to name just a few).
Newborn Screening Test Developed For Rare, Deadly Neurological Disorder
Scientists have developed a new dried blood spot screening test for Niemann-Pick type C, with goal to speed diagnosis and treatment.
New Autism Blood Biomarker Identified
Researchers at UT Southwestern Medical Center have identified a blood biomarker that may aid in earlier diagnosis of children with autism spectrum disorder, or ASD.
Autism, Cancer Share a Remarkable Number of Risk Genes
Researchers with the UC Davis Comprehensive Cancer Center, MIND Institute identify more than 40 common genes.
Number Of Known Genetic Risk Factors For Endometrial Cancer Doubled
An international collaboration of researchers has identified five new gene regions that increase a woman’s risk of developing endometrial cancer, one of the most common cancers to affect women, taking the number of known gene regions associated with the disease to nine.
Five New Breast Cancer Genes Found
Discovery of mutations paves the way for personalised treatment of breast cancer.
Releasing Cancer Cells for Better Analysis
A new device developed at the University of Michigan could provide a non-invasive way to monitor the progress of an advanced cancer treatment.
Releasing Cancer Cells for Better Analysis
A new device developed at the University of Michigan could provide a non-invasive way to monitor the progress of an advanced cancer treatment.
Magnetic Nanoparticles May Reveal Early Traces Of Cancer
Rice University students’ computer program aids MD Anderson diagnostic initiative .
New Blood Test for The Earlier Diagnosis of Breast Cancer Spread
Researchers at University of Westminster have confirmed that a new blood test can detect if breast cancer has spread to other parts of the body.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,500+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!